TIGIT class of checkpoint inhibitors fails with Keytruda March 17, 2023 - Merck's (MSD) co-formulation of Keytruda and anti-TIGIT therapy vibostolimab did not improve progression-free survival compared to chemotherapy alone in patients with metastatic non-small cell lung cancer that had previously been treated with immunotherapy and platinum-doublet chemotherapy.
This failure suggests that the hypoxic TME was unable to be remodeled nor could the innate system be "primed" for Merck's anti-PD-1 Keytruda to work.
These results add further credibility to the affect of ONCY's pelareorep on remodeling the TME and pelareorep's ability to "prime" both the innate and adaptive immune systems prior to the addition of a PD-(L)1 checkpoint inhibitor like Keytruda or Tecentriq or Bavencio, for example.
https://www.fiercebiotech.com/biotech/merck-tacks-another-loss-anti-tigits-company-not-losing-hope-larger-strategy